HomeIONS • NASDAQ
Follow
Ionis Pharmaceuticals Inc
Previous close
$40.91
Day range
$40.77 - $41.53
Year range
$34.32 - $54.44
Market cap
5.95B USD
Avg Volume
974.30K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 324.50M | 113.65% |
Operating expense | 51.01M | 6.38% |
Net income | -9.26M | 82.33% |
Net profit margin | -2.85 | 91.74% |
Earnings per share | 0.12 | 109.98% |
EBITDA | 18.74M | 109.26% |
Effective tax rate | -234.77% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 2.34B | 17.03% |
Total assets | 2.99B | 18.00% |
Total liabilities | 2.60B | 32.76% |
Total equity | 386.69M | — |
Shares outstanding | 145.75M | — |
Price to book | 15.26 | — |
Return on assets | 1.31% | — |
Return on capital | 1.68% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -9.26M | 82.33% |
Cash from operations | 32.86M | 116.42% |
Cash from investing | -26.71M | -112.59% |
Cash from financing | 40.72M | 179.82% |
Net change in cash | 47.21M | 222.55% |
Free cash flow | 58.22M | 149.63% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
927